TrialBMC endocrine disorders2022

Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial.

Azizul Hasan Aamir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.